ENTA ENTA

Enanta Pharmaceuticals Stock Price

42.37
-0.69 (-1.6%)
Upgrade to Real-Time
Afterhours (Closed)
42.37
Volume 121,006
Bid Price 20.27
Ask Price 54.68
News -
Day High 42.92

Low
37.59

52 Week Range

High
83.23

Day Low 41.73
Company Name Stock Ticker Symbol Market Type
Enanta Pharmaceuticals Inc ENTA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.69 -1.6% 42.37 16:28:54
Open Price Low Price High Price Close Price Prev Close
42.76 41.73 42.92 42.37 43.06
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,847 121,006 $ 42.35 $ 5,124,060 - 37.59 - 83.23
Last Trade Time Type Quantity Stock Price Currency
16:12:07 28 $ 42.37 USD

Period:

Draw Mode:

Enanta Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 881.19M 20.80M 16.10M $ 86.16M $ -70.62M -5.91 -7.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 534.00k 7.00%

more financials information »

Enanta Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ENTA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week41.1045.5039.9843.11184,9901.273.09%
1 Month42.6549.7039.6044.18177,809-0.28-0.66%
3 Months62.1963.0039.6048.05197,475-19.82-31.87%
6 Months43.5676.3638.4151.47220,749-1.19-2.73%
1 Year82.5683.2337.5956.85225,576-40.19-48.68%
3 Years63.57102.0037.5954.79186,609-21.20-33.35%
5 Years48.26127.7737.5967.90199,738-5.89-12.2%

Enanta Pharmaceuticals Description

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.